Cargando…
Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor Agonists
[Image: see text] The human 5-HT(2) receptor subtypes have high sequence identity in their orthosteric ligand-binding domain, and many agonists are poorly selective between the 5-HT(2A) and 5-HT(2C) subtypes. Nevertheless, their activation is associated with different pharmacological outcomes. We sy...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016908/ https://www.ncbi.nlm.nih.gov/pubmed/32064387 http://dx.doi.org/10.1021/acsomega.9b03430 |
_version_ | 1783497083609677824 |
---|---|
author | Yempala, Thirumal Brea, José Loza, María Isabel Matthies, Douglas J. Zapata-Torres, Gerald Cassels, Bruce K. |
author_facet | Yempala, Thirumal Brea, José Loza, María Isabel Matthies, Douglas J. Zapata-Torres, Gerald Cassels, Bruce K. |
author_sort | Yempala, Thirumal |
collection | PubMed |
description | [Image: see text] The human 5-HT(2) receptor subtypes have high sequence identity in their orthosteric ligand-binding domain, and many agonists are poorly selective between the 5-HT(2A) and 5-HT(2C) subtypes. Nevertheless, their activation is associated with different pharmacological outcomes. We synthesized five phenethylamine analogs in which the benzene ring is replaced by a bulky dibenzo[b,d]furan moiety and found a couple with >70-fold 5-HT(2C) selectivity. Molecular docking studies of the most potent compound (5) at both receptor subtypes revealed the likely structural basis of its selectivity. Although in both cases, some crucial interactions are conserved, the change of the Ala222(5.46) residue in the 5-HT(2C) receptor to the larger Ser242(5.46) in the 5-HT(2A) subtype, which is the only structural difference between the orthosteric binding pockets of both receptors, weakens a π–π stacking interaction between the dibenzofuran moiety and the important Phe(6.52) residue and breaks a hydrogen bond between the dibenzofuran oxygen and Ser(5.43), explaining the selectivity of compound 5 for the 5-HT(2C) receptor. We believe that this effect of the residue at position 5.46 merits further exploration in the search for selective 5-HT(2C) receptor agonists that are of considerable interest in the treatment of schizophrenia and substance abuse. |
format | Online Article Text |
id | pubmed-7016908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-70169082020-02-14 Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor Agonists Yempala, Thirumal Brea, José Loza, María Isabel Matthies, Douglas J. Zapata-Torres, Gerald Cassels, Bruce K. ACS Omega [Image: see text] The human 5-HT(2) receptor subtypes have high sequence identity in their orthosteric ligand-binding domain, and many agonists are poorly selective between the 5-HT(2A) and 5-HT(2C) subtypes. Nevertheless, their activation is associated with different pharmacological outcomes. We synthesized five phenethylamine analogs in which the benzene ring is replaced by a bulky dibenzo[b,d]furan moiety and found a couple with >70-fold 5-HT(2C) selectivity. Molecular docking studies of the most potent compound (5) at both receptor subtypes revealed the likely structural basis of its selectivity. Although in both cases, some crucial interactions are conserved, the change of the Ala222(5.46) residue in the 5-HT(2C) receptor to the larger Ser242(5.46) in the 5-HT(2A) subtype, which is the only structural difference between the orthosteric binding pockets of both receptors, weakens a π–π stacking interaction between the dibenzofuran moiety and the important Phe(6.52) residue and breaks a hydrogen bond between the dibenzofuran oxygen and Ser(5.43), explaining the selectivity of compound 5 for the 5-HT(2C) receptor. We believe that this effect of the residue at position 5.46 merits further exploration in the search for selective 5-HT(2C) receptor agonists that are of considerable interest in the treatment of schizophrenia and substance abuse. American Chemical Society 2020-01-27 /pmc/articles/PMC7016908/ /pubmed/32064387 http://dx.doi.org/10.1021/acsomega.9b03430 Text en Copyright © 2020 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes. |
spellingShingle | Yempala, Thirumal Brea, José Loza, María Isabel Matthies, Douglas J. Zapata-Torres, Gerald Cassels, Bruce K. Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor Agonists |
title | Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor
Agonists |
title_full | Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor
Agonists |
title_fullStr | Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor
Agonists |
title_full_unstemmed | Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor
Agonists |
title_short | Dibenzofuranylethylamines as 5-HT(2A/2C) Receptor
Agonists |
title_sort | dibenzofuranylethylamines as 5-ht(2a/2c) receptor
agonists |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016908/ https://www.ncbi.nlm.nih.gov/pubmed/32064387 http://dx.doi.org/10.1021/acsomega.9b03430 |
work_keys_str_mv | AT yempalathirumal dibenzofuranylethylaminesas5ht2a2creceptoragonists AT breajose dibenzofuranylethylaminesas5ht2a2creceptoragonists AT lozamariaisabel dibenzofuranylethylaminesas5ht2a2creceptoragonists AT matthiesdouglasj dibenzofuranylethylaminesas5ht2a2creceptoragonists AT zapatatorresgerald dibenzofuranylethylaminesas5ht2a2creceptoragonists AT casselsbrucek dibenzofuranylethylaminesas5ht2a2creceptoragonists |